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Available online 16 June 2016Introduction: Systemic thromboembolism is a serious morbidity andmortality cause for patients with rheumatic
mitral stenosis (RMS). Previously conducted researches showed that spontaneous echo contrast (SEC) found in
the left atrium can constitute a risk factor for thrombus formation. The aim of this study is to evaluate the role
of echocardiographic and hematologic parameters in anticipating the presence of SEC in the left atrium of
patients with moderate–severe RMS.
Methods: This retrospective study includes all patients who were diagnosed with moderate–severe RMS and
underwent a transesophageal echocardiography between 2011 and 2014. Theywere then divided in two groups
depending on SEC presence; a SEC negative group and a SEC positive group.
Results: There were 33 patients (32%) in the SEC negative group and 71 patients (68%) in the SEC positive group.
The mean platelet volume was found to be signiﬁcantly higher in the SEC positive group (10.0 ± 1.3 vs. 11.6 ±
1.4, p b 0.001). To identify the factors affecting the presence of SEC, amultivariate analysis of the hematologic pa-
rameters was conducted and the mean platelet volume was found to be an independent predictor (odds ratio
1.913, 95% conﬁdence interval 1.300–2.814; p = 0.001). In the receiver operating characteristics curve analysis,
a mean platelet volume N11.8 ﬂ had a 55% sensitivity and 92% speciﬁcity in predicting SEC in patients withmitral
stenosis.
Conclusion: Mean platelet volume constitutes an independent risk factor for the presence of left atrial SEC in
patients with moderate–severe mitral valve stenosis.
© 2016 The Society of Cardiovascular Academy. Production and hosting by Elsevier B.V. All rights reserved. This is




Especially in developing countries, rheumatic mitral stenosis (RMS)
is still a major health concern.1 Patients with RMS show an elevated risk
for systemic thromboembolism, which becomes a primary mortality
and morbidity cause.2 Among the suggested mechanisms leading to
the disease are autoimmunity, inﬂammation and increased thrombotic
activity.3–5
Spontaneous echo contrast (SEC) is the presence of smoke – like
echoes with a characteristic swirling motion of blood found during
echocardiography.6 Previously conducted researches showed that
presence of SEC in the left atrium can constitute a risk factor for throm-
bus formation.7 In patients with RMS the risk of thrombosis and left
atrial SEC development is eventually higher.8 The aim of this study isResearch Hospital, Cardiology
0 505 400 7509; fax: +90 242
diovascular Academy.
y. Production and hosting by Elsevto investigate the relationship between the presence of SEC and related
hematologic parameters in patients with moderate–severe RMS.
Methods
In this retrospective study all moderate–severe RMS patients, who
had a percutaneous mitral balloon valvuloplasty between 2011 and
2014 in our clinic were included (mitral valve area b 1.5 cm2). Their
respective electrocardiograms were inspected and the rhythm deﬁned.
The exclusion criteria for the present studywere left atrial thrombus
formation, signiﬁcant mitral regurgitation (grade N 1), other moderate
or severe valve disease, history of malignancy, history of inﬂammatory
disease, current therapy with corticosteroids, connective tissue disease,
thyroid disease, other hematological disease and acute infectious
disease. A medical history was recorded from patient anamnesis form.
Transesophageal echocardiography (TEE) and transthoracic echo-
cardiography (TTE) records were also investigated (EPIQ 7 Ultrasound
System, Philips, Heide, Netherlands). All the echocardiographic ﬁndings
were carefully evaluated by two separate cardiologists. All measure-
ments were taken according to the recommendations of the American
Society of Echocardiography.9 The mean value of 3 measurements wasier B.V. All rights reserved. This is an open access article under the CC BY-NC-ND license
Table 1
Demographic characteristics of the groups according to the SEC presence.
Variable
SEC negative SEC positive
P value
(n = 33) (n = 71)
Age, years 43.6 ± 14.5 47.0 ± 11.3 0.286
Female, n (%) 28 (84%) 52 (73%) 0.062
DM, n (%) 3 (11.5%) 13 (16.7%) 0.755
Hypertension, n (%) 11 (42.3%) 37 (47.4%) 0.650
TC, mg/dl 189.0 ± 42.9 184.3 ± 36.5 0.417
LDL, mg/dl 125.5 ± 34.5 115.0 ± 34.6 0.106
HDL, mg/dl 45.0 ± 9.3 42.2 ± 8.3 0.119
Trygliceride, mg/dl 98.9 ± 43.3 122.2 ± 59.1 0.072
AF, n (%) 11 (33%) 28 (40%) 0.634
Aspirin, n (%) 17 (51%) 38 (53%) 0.248
Warfarin, n (%) 12 (38%) 29 (41%) 0.228
Beta blocker, n (%) 16 (48%) 36 (51%) 0.728
(Data are expressed as mean ± standard deviation for normally distributed data and
percentage for categorical variables).
(AF: atrial ﬁbrillation, DM: diabetes mellitus, HDL: high density lipoprotein, LDL: low
density lipoprotein, TC: total cholesterol).
Table 2
Echocardiographic characteristics of the groups according to the SEC presence (variables
with normal distribution were expressed as mean ± SD).
Variable
SEC negative SEC positive
P value
(n = 33) (n = 71)
LVEF, % 62.1 ± 4.2 62.0 ± 4.4 0.682
LA diameter, mm 44.7 ± 2.2 46.3 ± 2.7 0.010
LAVI, ml/m2 32.1 ± 8.2 33.4 ± 7.2 0.378
LVEDD, mm 44.0 ± 4.0 46.1 ± 5.0 0.128
LVESD, mm 28.3 ± 4.4 30.1 ± 5.0 0.090
MVA, cm2 1.1 ± 0.2 1.0 ± 0.2 0.423
Peak gradient, mm Hg 24.5 ± 9.2 21.9 ± 7.7 0.679
Mean gradient, mm Hg 14.5 ± 6.2 13.1 ± 6.2 0.317
WS 7.0 ± 2.2 9.6 ± 2.8 b0.001
Valve mobility 1.7 ± 0.6 2.4 ± 0.7 b0.001
Subvalvular 1.6 ± 0.6 2.4 ± 0.9 b0.001
Valve thickness 1.9 ± 0.7 2.5 ± 0.8 0.004
Calciﬁcation 1.7 ± 0.9 2.3 ± 0.9 0.010
sPAP, mm Hg 43.9 ± 13.4 40.7 ± 8.7 0.365
(LA: left atrium, LAVI: left atrial volume index, LVEF: left ventricular ejection fraction,
LVEDD: left ventricular end diastolic diameter, LVESD: left ventricular end systolic diame-
ter, MVA: mitral valve area, SEC: spontaneous echo contrast, WS: Wilkins score).
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measurements from patients with atrial ﬁbrillation. Routine echocar-
diographic measurements were also recorded. The planimetric mea-
surements of the mitral valve area were also conducted. The mitral
valve was assessed by TEE. TheWilkins score was determined by rating
the severity of leaﬂet mobility, leaﬂet thickening, leaﬂet calciﬁcation
and subvalvular thickening with a score of 0–4 and then adding the
results together.10 Left atrial SEC presence and degree was asses by
TEE according to the criteria laid down by Fatkin et al.11 The patients
were then divided into two groups; a SEC positive group and a SEC
negative one.
On the TEE day, the patients had blood drown from the antecubital
vein and underwent routine biochemistry and complete blood count
(CBC) tests, after a 12 hour fast. CBC including white blood cell (WBC),
neutrophil and lymphocyte counts,meanplatelet volume (MPV, normal
range: 7.4–10.4 ﬂ) were done using an automatized CBC count device
(Abott Cell Dyn, Illinois USA). The C-reactive protein (CRP) levels
(normal range: 0–5 mg/L) were analyzed with a Beckman Coulter Inc.
(Image 800, California, USA).
Statistical analysis
Data were analyzed with the SPSS software version 21.0 for
Windows (SPSS Inc., Chicago, IL, USA). Continuous variables were
expressed as mean + SD, and categorical variables are expressed as
percent. The χ2 test and Fisher's exact test were used to compare
categorical variables. The Shapiro–Wilk test was used to assess the dis-
tribution of continuous variables. Student's t-test was used for variables
with normal distribution and the values were presented as mean± SD.
Continuous variables without normal distribution were analyzed using
Mann–Whitney U test. Receiver operating characteristic (ROC) curve
analysis was performed to identify optimal cutoff values for MPV. The
effects of different variables on SEC were calculated in univariate analy-
sis for each. The variables for which the unadjusted P-value was 0.10 in
logistic regression analysis were identiﬁed as potential riskmarkers and
included in the full model. The odds ratios (OR) and 95% conﬁdence
intervals (CI)were calculated. A two-tailed p-value of b0.05was consid-
ered statistically signiﬁcant.
Results
104 patients were included in this study of which 80 (77%) were
female. 33 of them (32%) were in the SEC negative group (mean age
43.6 + 14.5) and 71 (68%) in the SEC positive group (mean age
47.0 + 11.3). Mean age, diabetes mellitus, hypertension, hyperlipid-
emia presence and aspirin or warfarin usage was similar among the
groups. Atrial ﬁbrillation (AF) was detected in 11 (33%) of the SEC
negative group patients and 28 (40%) in the SEC positive one (p =
0.634). Also, in 31 of the 39 patients who had AF (79%) and in 48 of
the 65 patients who did not have AF (73%), SEC presence was detected
(p = 0.632). The groups' baseline characteristics are shown in Table 1.
The Wilkins score (9.6 ± 2.8 vs. 7.0 ± 2.2, p b 0.001) and the left
atrial diameter (46.3 ± 2.7 mm vs. 44.7 ± 2.2 mm, p = 0.010) were
found to be signiﬁcantly higher in the SEC positive group. There was
no signiﬁcant difference among groups with regard to the mitral valve
area (1.0 + 0.2 vs. 1.1 + 0.2, p = 0.423). TTE and TEE ﬁndings are
shown in Table 2.
There was no signiﬁcant difference among the groups with respect
to some hematologic parameters like WBC count, platelet count, red
cell distribution width and CRP (Table 3). However, MPV (11.6 ± 1.4
vs 10.0 ± 1.3, p b 0.001) was found to be signiﬁcantly higher in the
SEC positive group (Fig. 1). A univariate logistic regression analysis
was performed in order to determine the factors leading to SEC
presence and MPV (OR = 1.972, 95% CI: 1.411–2.758; p b 0.001),
Wilkins score (OR = 1.409, 95% CI: 1.172–1.693, p b 0.001) and left
atrial diameter (OR = 1.265, 95% CI: 1.051–1.522; p = 0.013) wereshown to be risk factors. Also, a multivariate logistic regression analysis
was performed in order to determine the factors leading to SEC pres-
ence and MPV value was found to be an independent predictor
(OR = 1.913, 95% CI: 1.300–2.814, p = 0.001) (Table 4). In the ROC
curve analysis, a MPV N 11.8 ﬂ had a 55% sensitivity and 92% speciﬁcity
in predicting SEC in patients with mitral stenosis (area under the curve
0.780, p b 0.001)(Fig. 2).
Discussion
Patients withmoderate–severe RMSwere included in this study and
23% of them were found to have SEC presence in their left atrium.
Univariate and multivariate analysis showed that Wilkins echo score,
MPV and left atrium diameter were risk factors related to left atrial
SEC presence. In addition to that, MPV N 11.8 ﬂ was found to have a
55% sensitivity and 92% speciﬁcity in predicting SEC presence in patients
with mitral stenosis.
SEC is a dynamic smoke-like echo with a characteristic swirling
motion of blood detected by echocardiography.12 In RMS patients
there is an increase in general inﬂammatory and prothrombotic state
and therefore the risk of stasis in the left atrium that will eventually
lead to left atrial SEC or thrombus, is signiﬁcantly higher than the nor-
mal population.13,14 In previous studies SEC was found to have a
frequency of 21–67% in RMS patients and systemic thromboembolism
was reported as an independent predictor of SEC presence.6,15,16 Some
Table 3
Common hemogram and inﬂammatory parameters of the groups according to the SEC
presence.
Variable
SEC negative SEC positive
P value
(n = 33) (n = 71)
Hemoglobin, g/dl 12.2 ± 1.2 13.0 ± 1.3 0.023
WBC, (× 103/μL) 7.8 ± 2.0 7.9 ± 2.3 0.892
Platelet count, (× 103/μL) 221.2 ± 69.3 236.6 ± 59.9 0.276
MPV, ﬂ 10.0 ± 1.3 11.6 ± 1.4 b0.001
RDW, % 15.2 ± 2.2 14.4 ± 1.9 0.073
CRP, mg/l 6.1 ± 5.5 6.1 ± 5.2 0.703
Variables with normal distribution were expressed as mean ± SD.
CRP: C-reactive protein, MPV: mean platelet volume, RDW: red blood cell distribution
width, WBC: white blood cells count.
Table 4
Evaluation of the factors affecting the presence of the SEC by univariate and multivariate
logistic regression analysis.
Univariate Multivariate
Variable OR (95% CI) P value Adjusted OR (95%CI) P value
Sex 0.123 (0.016–0.959) 0.046
Hemoglobin 1.552 (1.072–2.246) 0.020 1.424 (0.950–2.134) 0.087
MPV 1.972 (1.411–2.758) b0.001 1.913 (1.300–2.814) 0.001
RDW 0.835 (0.677–1.031) 0.093
CRP 0.996 (0.919–1.079) 0.926
Trygliceride 1.009 (0.999–1.019) 0.072
LA diameter 1.265 (1.051–1.522) 0.013 1.007 (0.997–1.017) 0.026
WS 1.409 (1.172–1.693) b0.001 1.345 (1.092–1.657) 0.005
LVEF 9.992 (0.894–1.100) 0.876
LVESD 1.126 (1.018–1.246) 0.022
Mean gradient 0.967 (0.903–1.036) 0.335
MVA 0.418 (0.050–3.476) 0.420
CRP: C-reactive protein, LA: left atrium, LVEF: left ventricle ejection fraction, MPV: mean
platelet volume,MVA:mitral valve area, RDW: red blood cell distributionwidth,WS:Wil-
kins score.
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patients are atrial ﬁbrillation, high Wilkins score, small mitral valve
area, increased mitral gradient, left atrial dilation without severe mitral
insufﬁciency.4,17 In a similar way, our study found that Wilkins score
was signiﬁcantly higher in the SEC positive group, but couldn't ﬁnd a
signiﬁcant association with mitral valve area and mitral gradient.
The pathophysiologicalmechanismof RMS is related to the antigenic
similarity of the streptococcal M protein with cardiac tissue and to the
related autoimmune response that follows. In the chronic state of the
disease, inﬂammation is persistent even without the presence of an
infectious agent.3,18 According to previous studies, inﬂammatory pre-
dictors were found to be elevated in RMS patients.4,19 Kaya et al. studied
the systemic inﬂammatory state predictors in RMS patients with SEC
presence and reported signiﬁcantly elevated values of high sensitive
CRP and neutrophil/lymphocyte ratio. Also, a neutrophil/lymphocyte
ratio N3.1 was found to have a speciﬁcity of 72% and a sensitivity of
80% in detecting left atrial SEC presence in this study.20
Increased prothrombotic state has also been reported, alongside in-
creased inﬂammation, in RMS patients. Previous studies have reported
increased MPV, P-selectin, ﬁbrinogen and D-dimer levels as conditions
related to the increased prothrombotic state in these patients.5,21,22 It
has also been shown that MPV values, in RMS patients, tend to decrease
after percutaneous mitral balloon valvuloplasty.22 MPV is one of the
indicators of platelet function. Bigger platelets are hemostatically
more reactive that smaller ones and an increase in MPV values, reﬂect
an increase in platelet function.23–25 Akpek et al. included 232 RMS
patients in their study and found that MPV values were correlated to
left atrial SEC presence and SEC degree.14 In a study conducted by İleri
et al., examined 84 patients with RMS, severe MR and left atrium SEC
presence have been shown to be associated with increased in MPV.26Fig. 1.MPV levels in the SEC negative and SEC positive patients.In a similar way, our study found that MPV values were higher in SEC
positive patients, compared to SEC negative patients. In addition to
this, our study found that a MPV N 11.8 ﬂ value was an independent
predictor of SEC presence.
Atrial ﬁbrillation is an important risk factor for the development of
left atrial SEC or thrombus.7 In addition to patients with AF, previous
studies have reported an increased hypercoagulable state in RMS
patients with sinus rhythm too.27 Risk factors associated with left atrial
thrombus are advanced age, atrial ﬁbrillation, small mitral valve area,
dilated left atrium and SEC presence.17,28 Munjunath et al. studied 848
RMS patients with sinus rhythm and reported that left atrial thrombus
did not form without a SEC presence.27 Therefore it is important to
detect SEC positive patients. Our study did not detect any signiﬁcant
difference among the groups with respect to atrial ﬁbrillation but
reported increased MPV values as independent predictors of SEC
presence. Despite being on sinus rhythm, patients with MPV N 11.8 ﬂ
had a higher probability of developing SEC and therefore should be reg-
ularly monitored with TEE. To investigate the need and effectiveness ofFig. 2. ROC curve analysis for MPV in prediction of SEC (area under the curve 0.780,
p b 0.001).
130 N. Bayar et al. / International Journal of the Cardiovascular Academy 2 (2016) 127–130anti-inﬂammatory, antiplatelet and anticoagulant therapy in these
patients, large randomized trials results are needed.
Study limitations
This study was a retrospective one. The possible limitations of the
present study include that it was a single-center experience and includ-
ed a small number of patients. Possibility of intermittent atrial ﬁbrilla-
tion cannot be ruled out. Measures of thromboembolic risk like left
atrial appendage size, and ﬁlling and emptying velocitieswere not stud-
ied. Because the majority of the included patients were expecting a
percutaneous mitral balloon valvuloplasty, those with severe mitral
insufﬁciency were not included. Therefore these results may not repre-
sent patients with severe mitral insufﬁciency.
Conclusion
Independently from cardiac rhythm, MPV value was found to be
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